J

Johnson & Johnson

Global healthcare company offering pharma, devices.

Customer Journey Engagement Director - Global Customer Solutions, Medtech Supply Chain

Full-TimeUpdated on 9/29/2026Deadline 10/30/26
$150k - $258.8k/yr+ Long-term incentive program
Expert
Bachelor's, Master's
Raritan, NJ, USA
HybridHybrid work is indicated; travel is approximately 10% globally and may occasionally reach 20%.

About the job

Requirements
  • A bachelor's degree is required.
  • At least 12 years of experience leading global customer service, process, capability, systems, or business transformation in a complex multi-region environment.
  • A strong track record leading multifunctional teams and aligning process, technology, commercial, and operational stakeholders around shared customer outcomes.
  • Demonstrated experience translating customer journeys and service blueprints into process, capability, and investment roadmaps.
  • Experience with customer-facing and transactional capabilities such as customer relationship management, case management, telephony, portals, order management, electronic data interchange/application programming interfaces, automation, or comparable solutions.
  • Demonstrated ability to partner with Product Owners, Technical Owners, Commercial teams, and regional Operations to shape requirements, priorities, and deployment plans.
  • Experience establishing governance, prioritization, performance measures, and continuous-improvement mechanisms across a global portfolio.
  • Strong people leadership, enterprise influence, commercial judgment, and communication skills, with the ability to lead through a peer-based operating model.
  • English language proficiency is required.
Responsibilities
  • Translate customer expectations and Jobs-to-be-Done captured in the Customer Service Blueprint into clear process, capability, and investment priorities.
  • Lead and align the Customer Journey Engagement portfolio across Process Architecture and Governance, Order to Invoice, Customer Interaction, Automation, and Order Connectivity.
  • Lead the measurement and continuous improvement of customer outcomes and operational performance, ensuring capability investments deliver measurable value.
  • Define and maintain a multi-year capability and investment roadmap, balancing customer value, operational needs, risk, scalability, and business priorities.
  • Establish an integrated governance model that enables peer capability leaders to make coordinated decisions across processes, data, technology, controls, and deployment.
  • Ensure the Process Architecture and Governance capability maintains Blueprint methodology, process taxonomy, standards, decision rights, and cross-portfolio coherence.
  • Partner with Product Owners and Technical Owners to translate business requirements into product roadmaps, technology solutions, and tools.
  • Partner with regional Customer Service Operations to deploy capabilities into roles, procedures, training, system configuration, and performance routines while allowing appropriate regional adaptation within global guardrails.
  • Guide Order Connectivity capabilities across electronic data interchange, application programming interfaces, and emerging channels to improve reliable, scalable customer-to-Johnson & Johnson transaction exchange.
  • Guide Customer Interaction capabilities across customer relationship management, case management, telephony, and customer portal solutions to support consistent customer interactions and self-service.
  • Advance automation and artificial intelligence opportunities that simplify work, improve productivity, and reduce non-value-added activity across the customer journey.
  • Provide direction for vendor management, productivity management, and differentiated customer collaboration approaches for priority strategic customers.
  • Define measures of success for capability investments and use customer outcomes, operational insights, local requirements, and performance data to inform prioritization and continuous improvement.
  • Build, coach, and develop a global organization of capability leaders and professionals; establish clear mandates, shared accountability, effective partnerships, and a customer-focused culture.
Desired Qualifications
  • An advanced degree.
  • Experience with customer journey management, service blueprinting, business process architecture, process standardization, or global governance models.
  • Practical experience with Microsoft Dynamics, Genesys, SAP, customer portals, or comparable enterprise platforms.
  • Experience with business-to-business connectivity, electronic data interchange/application programming interface ecosystems, digital order channels, or complex customer integrations.
  • Background in regulated environments such as healthcare or life sciences and familiarity with relevant compliance expectations.
  • Experience scaling automation, artificial intelligence, or productivity initiatives based on measurable business and customer outcomes.
  • Experience working across global and regional Customer Service organizations and with outsourced operational partners.

About the company

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 sales rose 6.6% to $25.3 billion, with raised full-year guidance.
  • TREMFYA posted $2 billion quarterly sales in July 2026, growing 72.5%.
  • CAPLYTA met its bipolar mania primary endpoint on September 21, 2026.

What critics are saying

  • Talc litigation still threatens cash flow after the $5.5 billion settlement announced July 2026.
  • Apollo's orthopedics talks signal DePuy Synthes weakness and forced portfolio shrinkage.
  • AbbVie's etentamig and biosimilars pressure CARVYKTI, TREMFYA, and post-STELARA growth.

What makes Johnson & Johnson unique

  • J&J has 28 billion-dollar products, reducing dependence on any single franchise.
  • TREMFYA and DARZALEX offset STELARA erosion, proving resilient portfolio management.
  • CAPLYTA, CARVYKTI, and RYBREVANT deepen leadership across psychiatry, cell therapy, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

↓ -2%

1 year growth

↓ -2%

2 year growth

↓ -1%
Yahoo Finance
Sep 18th, 2026
J&J stock trades at 28x earnings, but STELARA biosimilar hit distorts valuation

Johnson & Johnson stock has surged 57% over the past year, outpacing the S&P 500's 17% return. Trading at approximately $270 per share, the stock appears expensive at 28.3 times trailing earnings. However, those trailing figures include STELARA, which lost market share to biosimilar competition and reduced operational sales growth by 460 basis points in Q2 2026. Excluding STELARA, the company achieved double-digit growth. The forward outlook looks more attractive, with the stock trading at 24.1 times fiscal 2026 earnings and 20.9 times 2027 estimates. Johnson & Johnson's portfolio includes 28 products generating over $1 billion annually each, with trailing twelve-month revenue near $98 billion. Meanwhile, TREMFYA grew 71% in Q2 2026, becoming the fastest-growing advanced therapy in Crohn's disease and ulcerative colitis. Operating margins improved to 26.8% from a three-year average of 25.7%, supporting expectations for continued margin expansion.

Yahoo Finance
Sep 14th, 2026
Apollo in talks to acquire J&J's orthopedics unit for $20B

Johnson & Johnson shares rose 1.3% in pre-market trading following reports that Apollo Global Management is in discussions to acquire its orthopedics business for approximately $20 billion. Bloomberg News reported the potential deal could be finalised within weeks, citing people familiar with the matter. The orthopedics division generated $9.3 billion in revenue in 2025. However, the business has faced thousands of lawsuits related to its hip replacement devices. No transaction has been confirmed. Investors responded positively to news of the reported discussions and the potential valuation of the orthopedics unit.

Yahoo Finance
Sep 3rd, 2026
J&J rises 1% as AbbVie's myeloma drug shows 74% response rate

Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.

Yahoo Finance
Sep 1st, 2026
P&G commits $10B in dividends amid 2.8B productivity savings while J&J's 28.5% stock surge masks mid-2027 spinoff risk

Procter & Gamble's dividend strategy is outpacing Johnson & Johnson's despite J&J's stronger stock performance this year. J&J's forward annualised dividend of $5.36 exceeds P&G's $4.354, but its planned mid-2027 DePuy Synthes spinoff threatens its dividend streak. P&G CEO Shailesh Jejurikar committed $10 billion in dividends and $5 billion in buybacks for fiscal 2027, supported by $2.8 billion in productivity savings. The company returned over $15 billion to shareholders in fiscal 2026, including more than $10 billion in dividends. J&J's stock surged 28.5% year-to-date versus P&G's 1.3% gain, driven by strong product performance. However, the upcoming spinoff poses uncertainty, as similar corporate events have disrupted other companies' dividend streaks. P&G faces no such structural risk.

Yahoo Finance
Aug 29th, 2026
J&J stock surges 52.8% in a year, outpacing consumer staples sector with strong pharma growth

Johnson & Johnson has significantly outperformed the consumer staples sector, with shares rising 52.8% over the past 52 weeks compared to the State Street Consumer Staples Select Sector SPDR Fund's 6.5% gain. The New Brunswick-based healthcare giant, valued at $640.5 billion, has seen particularly strong momentum recently, climbing 16.1% over three months. The company's strong performance follows solid second-quarter results released on 15 July, where sales increased 6.6% year-over-year to $25.31 billion. Adjusted earnings per share of $2.90 exceeded market expectations. Johnson & Johnson raised its full-year guidance, projecting adjusted EPS of $11.58 and sales of $101.1 billion. The stock currently trades just 3.1% below its 52-week high of $276.47, reached on 19 August.